PEGylated lipid bilayer-wrapped nanographene oxides for synergistic co-delivery of doxorubicin and rapamycin to prevent drug resistance in cancers
- Title
- PEGylated lipid bilayer-wrapped nanographene oxides for synergistic co-delivery of doxorubicin and rapamycin to prevent drug resistance in cancers
- Author
- 최한곤
- Keywords
- doxorubicin; rapamycin; graphene oxide; liposome; chemo-photothermal therapy
- Issue Date
- 2017-07
- Publisher
- IOP PUBLISHING LTD
- Citation
- NANOTECHNOLOGY, v. 28, No. 29, Article no. 295101
- Abstract
- Nano-graphene oxide (nGO) is a carbon allotrope studied for its potential as carrier for chemotherapeutic delivery and its photoablation effects. However, interaction of nGO with blood components and the subsequent toxicities warrant a hybrid system for effective cancer drug delivery. Combination chemotherapy aids in effective cancer treatment and prevention of drug resistance. Therefore, in this study, we attempted to prepare polyethylene glycosylated (PEGylated) lipid bilayer-wrapped nGO co-loaded with doxorubicin (DOX) and rapamycin (RAPA), GOLDR, for the prevention and treatment of resistant cancers. Our results revealed a stable GOLDR formulation with appropriate particle size (similar to 170 nm), polydispersity (similar to 0.19) and drug loading. Free drug combination (DOX and RAPA) presented synergistic anticancer effects in MDA-MB-231, MCF-7, and BT474 cells. Treatment with GOLDR formulation maintained this synergism in treated cancer cells, which was further enhanced by the near infrared (NIR) laser irradiation-induced photothermal effects of nGO. Higher chromatin condensation and apoptotic body formation, and enhanced protein expression of apoptosis-related markers (Bax, p53, p21, and c-caspase 3) following GOLDR treatment in the presence of NIR laser treatment clearly suggests its superiority in effective chemo-photothermal therapy of resistant cancers. The hybrid nanosystem that we developed provides a basis for the effective use of GOLDR treatment in the prevention and treatment of resistant cancer types.
- URI
- http://iopscience.iop.org/article/10.1088/1361-6528/aa7997/metahttps://repository.hanyang.ac.kr/handle/20.500.11754/72230
- ISSN
- 0957-4484; 1361-6528
- DOI
- 10.1088/1361-6528/aa7997
- Appears in Collections:
- COLLEGE OF PHARMACY[E](약학대학) > PHARMACY(약학과) > Articles
- Files in This Item:
There are no files associated with this item.
- Export
- RIS (EndNote)
- XLS (Excel)
- XML